density and sperm motility were 29 years, 2.9 mL, 28 x 106/mL, and 43%, respectively. Patients with TC had significantly lower total sperm concentration (P¼0.008) and motile sperm rate (P¼0.012) compared with other malignancies. The fertile range of the sperm from cancer patients were significantly poor in the TC (fertile 0%, intermediate 31%, and subfertile 69%) compared with other malignancies (12%, 42%, and 46%, respectively) (P¼0.044). In TC patients, the ratio of oligozoospermia was significantly higher in comparison with other malignancies (P<0.001). There were no significant differences in sperm parameters between seminoma and nonseminoma, whereas ratio of oligozoospermia was significantly greater in non-seminoma group than seminoma group (P<0.001). Among 29 TC patients, 3 patients (10%) had undergone infertility treatment, and 2 patients (7%) archived pregnancy and resulted in 2 deliveries.
density and sperm motility were 29 years, 2.9 mL, 28 x 106/mL, and 43%, respectively. Patients with TC had significantly lower total sperm concentration (P¼0.008) and motile sperm rate (P¼0.012) compared with other malignancies. The fertile range of the sperm from cancer patients were significantly poor in the TC (fertile 0%, intermediate 31%, and subfertile 69%) compared with other malignancies (12%, 42%, and 46%, respectively) (P¼0.044). In TC patients, the ratio of oligozoospermia was significantly higher in comparison with other malignancies (P<0.001). There were no significant differences in sperm parameters between seminoma and nonseminoma, whereas ratio of oligozoospermia was significantly greater in non-seminoma group than seminoma group (P<0.001). Among 29 TC patients, 3 patients (10%) had undergone infertility treatment, and 2 patients (7%) archived pregnancy and resulted in 2 deliveries. CONCLUSIONS: Men with testicular cancer have lower semen quality compared to those with other malignancies. The rate of using cryo-thawed sperm from cancer patients for fertility treatments in our unit was 10%.
Source of Funding: none

PD53-10 IMPACT OF ADJUVANT TREATMENT ON LONG-TERM QUALITY OF LIFE OF TESTICULAR CANCER SURVIVORS
Trung Q Ngo*, Jeremy R Goad, Anthony J Dowling, Lih-Ming Wong, Fitzroy, Victoria, Australia INTRODUCTION AND OBJECTIVES: Issues of survivorship of testicular cancer are emerging due to excellent results from treatment. Treatment generally consists of orchidectomy followed by active surveillance or adjuvant therapy with chemotherapy, radiotherapy or retroperitoneal lymph node dissection. The 10-year overall survival rate for testicular cancer is 95%. The objective of this project is to determine the effect of adjuvant therapy, education, cancer stage and age of diagnosis on the long-term quality of life of testicular cancer survivors.
METHODS: 144 patients were identified to have received treatment for testicular cancer at St Vincent's Hospital in Melbourne from 2001-2016. Patients were contacted by phone and mail. A validated cancer questionnaire (EORTC QLQ-C30) with a testicular cancer module (EORTC QLQ-TC26) was used. Questionnaire answers were recorded on a Likert scale and converted to a score from 0-100 according to the official scoring manual. Independent t-tests compared domain scores between different treatments, educational levels, cancer stages and age groups.
RESULTS: The response rate was 40% (57/144). Nine patients were deceased, and the median follow-up after orchidectomy was 42 months. Patients who received adjuvant therapy reported more financial difficulties than those who received surveillance alone (Figure 1) . However, there were no differences in global quality of life or other domains between different treatments (Figure 2 ). Those who were tertiary educated were more comfortable communicating with their partners about their disease and sexuality. Men with stage 2 disease or above reported lower social functioning than those with stage 1 disease. Finally, men who were older at the time of diagnosis reported a more positive outlook about the future and fewer concerns about infertility.
CONCLUSIONS: Clinicians could tailor counselling according to age, educational level, cancer stage and financial status at diagnosis. Importantly, patients could be reassured that the treatment chosen will not have a significant impact on long-term quality of life.
Source of Funding: None
PD53-11 PRIMARY RETROPERITONEAL LYMPH NODE DISSECTION (RPLND) IN STAGE II A/B SEMINOMA PATIENTS WITHOUT ADJUVANT TREATMENT: A PHASE II TRIAL (PRIMETEST)
Achim Lusch*, Laura Gerbaulet, Christian Winter, Peter Albers, Duesseldorf, Germany INTRODUCTION AND OBJECTIVES: To evaluate progression-free survival of stage II A/B seminoma patients (pts) undergoing primary retroperitoneal lymph node dissection (RPLND) without adjuvant treatment. To date there are only few publications reporting primary RPLND in Stage II seminoma. Aim is to present initial data of a feasibility study and a prospective phase II trial.
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